Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash from Financing Activities (2016 - 2025)

CorMedix's Cash from Financing Activities history spans 13 years, with the latest figure at -$1.4 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 112.52% year-over-year to -$1.4 million; the TTM value through Dec 2025 reached $238.5 million, up 806.01%, while the annual FY2025 figure was $238.5 million, 806.01% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was -$1.4 million at CorMedix, down from $150.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $150.5 million in Q3 2025 and bottomed at -$1.4 million in Q4 2025.
  • The 5-year median for Cash from Financing Activities is $6.1 million (2025), against an average of $22.1 million.
  • The largest YoY upside for Cash from Financing Activities was 7778.42% in 2025 against a maximum downside of 112.52% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $176992.0 in 2021, then soared by 3315.74% to $6.0 million in 2022, then rose by 19.1% to $7.2 million in 2023, then skyrocketed by 56.73% to $11.3 million in 2024, then plummeted by 112.52% to -$1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Cash from Financing Activities are -$1.4 million (Q4 2025), $150.5 million (Q3 2025), and $83.2 million (Q2 2025).